Mitochondria-targeted half-sandwich iridium(<scp>iii</scp>)-Cp*-arylimidazophenanthroline complexes as antiproliferative and bioimaging agents against triple negative breast cancer cells MDA-MB-468-Reference-Cited by-同舟云学术

Mitochondria-targeted half-sandwich iridium(iii)-Cp*-arylimidazophenanthroline complexes as antiproliferative and bioimaging agents against triple negative breast cancer cells MDA-MB-468

Published:2022 Issue:19 Volume:12 Page:11953-11966
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Mondal Ashaparna¹^ORCID,Shanavas Shanooja²^ORCID,Sen Utsav²^ORCID,Das Utpal¹^ORCID,Roy Nilmadhab¹^ORCID,Bose Bipasha²^ORCID,Paira Priyankar¹^ORCID

Affiliation:

1. Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore-632014, Tamilnadu, India

2. Department Stem Cells and Regenerative Medicine Centre, Institution Yenepoya Research Centre, Yenepoya University, University Road, Derlakatte, Mangalore 575018, Karnataka, India

Abstract

Mitochondria targeting half-sandwich Iridium(iii)-Cp*-arylimidazophenanthroline complexes have been developed for MDA-MB-468 cell therapy and diagnosis.

Funder

Science and Engineering Research Board

Indian Council of Medical Research

VIT University

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2022/RA/D2RA01036D

Reference31 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries